 | Up a level |
Acs, Balazs; Leung, Samuel C Y; Kidwell, Kelley M; Arun, Indu; Augulis, Renaldas; Badve, Sunil S; Bai, Yalai; Bane, Anita L; Bartlett, John M S; Bayani, Jane; Bigras, Gilbert; Blank, Annika; Buikema, Henk; Chang, Martin C; Dietz, Robin L; Dodson, Andrew; Fineberg, Susan; Focke, Cornelia M; Gao, Dongxia; Gown, Allen M; ... (2022). Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern pathology, 35(10), pp. 1362-1369. Springer Nature 10.1038/s41379-022-01104-9
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
